Discovery of novel, potent, isosteviol-based antithrombotic agents

Eur J Med Chem. 2019 Dec 1:183:111722. doi: 10.1016/j.ejmech.2019.111722. Epub 2019 Sep 19.

Abstract

Thrombosis is a pathological coagulation process and can lead to many serious thrombotic diseases. Here, we report a novel potent antithrombotic compound (6k) based on isosteviol with anticoagulant and antiplatelet activities. 6k selectively inhibited FXa (Ki = 0.015 μM) against a panel of serine proteases and showed excellent anticoagulant activity (significant prolongation of ex vivo PT and aPTT over the vehicle, p < 0.01). 6k also significantly inhibited ADP-induced platelet aggregation in rats relative to the vehicle (p < 0.01). Furthermore, 6k exhibited potent ex vivo and in vivo antithrombotic activity in rats relative to the vehicle (p < 0.01 and p < 0.0001, respectively). Novel structure 6k, with potent antithrombotic activity, is expected to lead a promising approach for the development of antithrombotic agents.

MeSH terms

  • Animals
  • Diterpenes, Kaurane / chemistry*
  • Diterpenes, Kaurane / pharmacology*
  • Drug Discovery
  • Factor Xa Inhibitors / chemistry
  • Factor Xa Inhibitors / pharmacology
  • Female
  • Fibrinolytic Agents / chemistry*
  • Fibrinolytic Agents / pharmacology*
  • Humans
  • Male
  • Partial Thromboplastin Time
  • Platelet Aggregation / drug effects
  • Platelet Aggregation Inhibitors / chemistry*
  • Platelet Aggregation Inhibitors / pharmacology*
  • Rats
  • Rats, Wistar
  • Thrombin / metabolism
  • Thrombosis / drug therapy*

Substances

  • Diterpenes, Kaurane
  • Factor Xa Inhibitors
  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors
  • isosteviol
  • Thrombin